The new one will enroll only men who have sex with men and transgender women who are at higher risk for HIV because they have multiple partners. The study will use Truvada, a two-drug pill made by Gilead Sciences and approved by the U.S. Food and Drug Administration in 2004 to treat people with HIV. The company, which has applied for FDA approval to market it for HIV prevention, is providing the drug for free. Study participants also will get counseling on reducing their risk for HIV.Each of the three study teams will investigate slightly different areas.UC San Diego will partner with San Diego County, Los Angeles County, the University of Southern California and the Long Beach health department to enroll 400 high-risk participants to get daily doses of Truvada. All 400 will get regular counseling and health assessments; half also will get a daily text message reminder to take the pill.
View the Original article
No comments:
Post a Comment